Study on the Effect of Desmucin Combined with Neuroprotective Therapy on Bone Metabolism Regulation and Cognitive Function Improvement in Osteoporosis Combined with Alzheimer's Disease
ZHANG Yaolin
PU Lunqing
ZENG Demiao
CHU Ming
ZHU Dong
FENG Rui
Abstract：Objective:To explore the regulatory effect of denosumab combined with neuroprotective therapy on bone metabolism and cognitive function improvement in patients with osteoporosis complicated with Alzheimer's disease.Method:62 patients with osteoporosis complicated with Alzheimer's disease(AD)who were treated at the First People's Hospital of Honghe Prefecture from January 2020 to June 2024 were seleted.The 62 patients were randomly divided into a control group(n=31)and a treatment group(n=31).The recovery of bone quality and cognitive function of patients with osteoporosis complicated with Alzheimer's disease in the two groups were compared.Result:Efficacy analysis demonstrated that the treatment group achieved an overall response rate of 87.10%(27/31),significantly outperforming the control group's 67.74%(21/31),with statistically significant differences between groups(P<0.05).Regarding bone mineral density(BMD),the treatment group showed markedly greater improvements in femoral neck and lumbar spine BMD compared to the control group,with statistically significant differences observed post-treatment(P<0.05).Biochemical marker analysis revealed no statistically significant differences in PINP,BGP,and B-CTX levels between groups before treatment(P>0.05).After treatment,both groups exhibited decreased Procollagen Type N-terminal Propeptied(PINP)and β-Carboxyterminal Collagen Telopeptiole of Type ⅠCollagen(β-CTX)levels,with the treatment group showing more pronounced reductions.Additionally,the treatment group demonstrated greater increases in Bone Gla-protein(BGP)levels than the control group,all reaching statistically significant levels(P<0.05).Cognitive function assessments indicated no statistically significant differences in ADAS-Cog and MoCA scores between groups before treatment(P>0.05).Post-treatment,both groups showed decreased scores,but the treatment group demonstrated significantly better improvement than the control group(P<0.05).Safety evaluations revealed no statistically significant differences in adverse reaction incidence rates between groups(P>0.05).Conclusion:Desumab combined with neuroprotective therapy can improve the bone metabolism regulation and cognitive function of patients with osteoporosis complicated with Alzheimer's disease,and can effectively promote bone recovery
Keywords：DesumabOsteoporosisAlzheimer's diseaseCognitive function
Publication Date：2025-11-15
Online Publishing Date：2025-12-17(First online date of this platform, not the publication date of the document)
Pages：5( 30-34 )